Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in high cardiovascular risk patients without prior myocardial infarction or stroke
NL-OMON60804Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Evolocumab with Placebo (2 arms). Primary endpoints: Time to CHD death, myocardial infarction, or ischemic stroke and Time to CHD death, myocardial infarction, ischemic stroke, or ischemia-driven arterial revascularization. Started May 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON60804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60804.